CytRx Corporation announced the engagement of Eric L. Curtis, MBA, to provide strategic counsel for the Company's ongoing programs, including its LADR (Linker Activated Drug Release) technology platform and ultra-high potency drug candidates, beginning with proof of concept through clinical development. Most recently, he has provided commercial and strategic consultancy services to a variety of life science companies through his consultancy practice, Curtis Biopharm Consulting.